Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per ...

Regions face reduced federal research funding and shrinking venture capital for startups, though rankings stay consistent.

Alnylam Pharmaceuticals, Inc. shares soar with strong Q2 results, driven by Amvuttra's stellar U.S. launch for ATTR ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock has underperformed the medical sector and S&P 500 Index in this timeframe.

Mediolanum International Funds Ltd has supercharged its investment in Regeneron Pharmaceuticals, increasing its stake by a ...

Key factors fueling this trend include increased awareness, improved healthcare infrastructure, and enhanced diagnostic and treatment accessibility. With the prevalence of high myopia projected to ...

Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

July 7 – With a 90-day negotiating period on country-specific US tariffs is set to expire on July 9, Trump enacts a multitude ...

The Tarrytown, New York-based company said it had profit of $12.81 per share. Earnings, adjusted for one-time gains and costs, were $12.89 per share. The results exceeded Wall Street expectations. The ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...